Connect with us
[ad_1] Newswise — HOUSTON & POHANG, South Korea – The University of Texas MD Anderson Cancer Center and C-Biomex Ltd. today announced a strategic research collaboration agreement...
[ad_1] Newswise — SAN DIEGO ― Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a...
[ad_1] Newswise — SAN DIEGO ― The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with...
[ad_1] Newswise — Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated early positive results from novel therapies targeting menin for...
[ad_1] Newswise — HOUSTON ― The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Data Science in Oncology (IDSO),...
[ad_1] Newswise — MADRID ― Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy – given before and after surgery – significantly improved event-free survival (EFS)...
[ad_1] Newswise — HOUSTON ― Jennifer Wargo, M.D., professor of Surgical Oncology and Genomic Medicine at The University of Texas MD Anderson Cancer Center, has been elected to the National Academy of...
[ad_1] Newswise — SINGAPORE ― Intensity-modulated radiation therapy (IMRT) should be the preferred choice when treating patients with locally advanced non-small cell lung cancer (NSCLC), as...
[ad_1] Newswise — HOUSTON and SAN MATEO, Calif. ― The University of Texas MD Anderson Cancer Center and Panacea Venture today announced the launch of Manaolana...
[ad_1] Newswise — HOUSTON ― A blood-based test developed by researchers at The University of Texas MD Anderson Cancer Center can predict an individual’s risk of dying from lung...
[ad_1] ABSTRACT: 4008 Newswise — CHICAGO ― HER2-targeted bispecific antibody zanidatamab demonstrated durable responses in patients with treatment-refractory HER2-positive biliary tract cancer (BTC), researchers from The...
[ad_1] Newswise — HOUSTON ― A new study led by researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Medicine, provides...
[ad_1] ABSTRACT: 7003 Treatment with luspatercept improved red blood cell counts and erythroid responses compared to treatment with epoetin alfa in patients with myelodysplastic syndromes (MDS),...
[ad_1] Newswise — HOUSTON ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These...